Epiregulin was detected in immersion fixed paraffin-embedded sections of human skin using Goat Anti-Human Epiregulin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1195) at 15 µg/mL overnight at 4 °C. ...read more
Recombinant Human Epiregulin protein was serially diluted 2-fold and captured by Rat Anti-Human Epiregulin Monoclonal Antibody (Catalog # MAB14252) coated on a Clear Polystyrene Microplate (Catalog # DY990). ...read more
Recombinant Human Epiregulin (Catalog # 1195-EP) stimulates proliferation in the Balb/3T3 mouse embryonic fibroblast cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human ...read more
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Epiregulin Antibody [Unconjugated]
Epiregulin is a member of the EGF family of growth factors which includes, among others, epidermal growth factor (EGF), transforming growth factor (TGF)-alpha, amphiregulin (ARG), HB (heparin-binding)-EGF, betacellulin, and the various heregulins. All EGF family members are synthesized as transmembrane precursors and are converted to soluble forms by proteolytic cleavage. Epiregulin was originally purified from the mouse fibroblast-derived tumor cell line NIH3T3/T7. The human epiregulin cDNA encodes a 169 amino acid (aa) residues transmembrane precursor with a 29 aa signal peptide, a 21 aa transmembrane domain and a 21 aa cytoplasmic domain. The putative soluble mature Epiregulin comprising the EGF-like domain (aa residues 64-104) is formed by proteolytic removal of the propeptide regions. There is 85% aa sequence homology between human and mouse epiregulins. Epiregulin is expressed primarily in the placenta and macrophages. High level expression has also been detected in various carcinomas. Epiregulin specifically binds EGF R (ErbB1) and ErbB4 but not ErbB2 and ErbB3. It activates the homodimers of both ErbB1 and ErbB4. In addition, epiregulin can also activate all possible heteromeric combinations of the four ErbB family members. Epiregulin stimulates the proliferation of fibroblasts, smooth muscle cells and hepatocytes. It has been shown to be an autocrine growth factor for epidermal keratinocytes as well as mesangial cells. Epiregulin has also been shown to inhibit growth of several epithelial tumor cells. In addition, Epiregulin has been implicated in the implantation process during pregnancy.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Epiregulin Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.